APTAMERS MARKET ANALYSIS

Aptamers Market Size and Trends

Global aptamers market is estimated to be valued at USD 7.29 Bn in 2024 and is expected to reach USD 22.93 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031.

To learn more about this report, request sample copy

Increasing research and development investment in pharmaceutical and biotechnology industries and growing application of aptamers in diagnostic, therapeutic development and drug discovery are some of the factors that are expected to drive the growth of global aptamers market. Aptamers have emerged as an alternative to antibodies due to their excellent binding affinity and specificity. Leading biotechnology and pharmaceutical companies are focusing on developing various aptamer-based therapeutics and diagnostics, and this boosts demand for aptamers. Growing focus of researchers and companies on developing precision medicine is further expected to accelerate the adoption of aptamers for disease treatment and diagnosis across the world.

Market Driver – Increasing Research and Development Activities by Various Universities  

Increasing research and development by various universities is expected to drive the global aptamers market growth over the forecast period. For instance, in June 2022, a team of researchers from Waseda University, Tokyo, Japan developed RaptGen. RaptGen is a variational auto encoder that efficiently discovers new aptamers which are not included in the input SELEX dataset. SELEX dataset is an activated database on selected randomized DNA/RNA sequences addressed to genomic sequence annotation. RaptGen is a novel computational model for aptamer generation.

Global aptamers market is expected to witness strong growth due to rising adoption of personalized medicine approach. Aptamers are increasingly being explored for their potential to enable personalized healthcare delivery by precisely recognizing molecular signatures of diseases, pathogens and patient health conditions. Significantly, aptamers can facilitate tailored therapeutic interventions and diagnosis by providing information about individual variations at the molecular level, arising from genetic or environmental factors. Their high target specificity and low immunogenicity makes them a strong key player than antibodies for developing companion diagnostics as well as therapeutics tailored for individuals or small patient subsets. Several pharmaceutical companies are evaluating aptamer candidates as biomarkers or targets for stratified medicine approaches aimed at identifying the right treatment options for the specific patients.